Markets
The money and the moves.
Capital, companies, and regulation across Singapore and Australia longevity, tracked as they happen. Every move dated and sourced.
Latest moves
What just happened.
- Singapore · IndustryNUS launches healthy longevity graduate certificate1 Jul
- Singapore · IndustryCan longevity be designed for everyone, not just the wealthy?1 Jul
- Singapore + Australia · CapitalTwo rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 202629 Jun
- AustraliaEverlab closes an AU$65M Series A16 Jun
- Trial milestone · SingaporePROMETHEUS advances to the XPRIZE Healthspan finals15 Apr
- Regulatory · GlobalFDA approves oral orforglipron (Foundayo)1 Apr
- GlobalInsilico Medicine lists on the Hong Kong Stock Exchange30 Dec
The universe
4 companies · 1 funds- Unity BiotechnologyNASDAQ · NASDAQ:UBX
Lead UBX1325 Ph2b FAILED Apr 2026; senolytic thesis impaired.
- Insilico MedicineHKEX · HKEX:3696
IPO 30 Dec 2025, largest 2025 HK biotech IPO; Temasek cornerstone.
Last move: 30 Dec
- Eli LillyNYSE · NYSE:LLY
Oral orforglipron ("Foundayo") FDA-approved 1 Apr 2026.
Last move: 1 Apr
- MesoblastASX · ASX:MSB / NASDAQ:MESO
Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD.
25
Events tracked, 2020 to 2026
US$369M
Disclosed capital across tracked events
15
Clinic launches and moves
17 / 5
Singapore events / Australia events
Capital timeline
Singapore Australia Global
Tap a dot for detail
25 events tracked
5 capital · 15 clinic · 4 research
Most recent
- ResMed acquires Noctrix Health
- Everlab Series A AU$65M
- NOVI partners with Novo Nordisk
- Oral orforglipron approved
Singapore and Australia, by category
Two markets, tracked side by side, never blended into one number.
Clinics
Capital
Research
Corporate
What variis tracks, continuously
Six beats the engine follows every day, not just when something breaks.
These are standing editorial tracks, not one-off stories. Each snapshot below is read live from the database.
Singapore
Morrow, Singapore launch
Open and operating in 2026; the recovery wing is phasing in. Leadership, licence, and pricing tracked in real time.
Open · Premium tier
Australia
Everlab, Australian expansion
Post-Series A growth: corporate-wellness deals, product additions, and the stated move into the UK.
Open · Premium tier
Science
NUS Academy and PROMETHEUS
Prof Andrea Maier's programme, the Clinical Trial Centre, and the PROMETHEUS trial's run through XPRIZE Healthspan.
500+ peer-reviewed publications
Capital
ASX longevity-adjacent watch
Mesoblast and the other ASX-listed names longevity investors track, the backbone of variis coverage in Australia.
Market cap ~A$2.6–2.8B
Capital
Brandon, Blackbird, Temasek
Singapore and Australia's largest longevity-relevant allocators, the capital bridge between the two markets.
AUM >A$1B across 6 funds
Regulatory
MOH and TGA developments
Healthcare Services Act 2020 enforcement in Singapore, TGA's Special Access Scheme in Australia. The backbone for operators and patients alike.
1 of 4 clinics publish a licence number
How an event qualifies
Three bars, and every entry has to clear all three.
- Dated
- A specific month, or year where no source publishes a month. Never a vague "recently".
- Sourced
- Traced to a public disclosure, regulatory filing, or verified press report, the same standard as every article.
- Market-relevant
- Moves capital, care, or regulation in Singapore or Australia specifically, not global news with a passing mention.
See how these numbers stack up entity by entity.
Sourced from public disclosures, regulatory filings, and verified press coverage. Not investment advice. See our editorial standards.